Completed PHASE3 INTERVENTIONAL 1-arm NCT03006445

Study of FYU-981 in Hyperuricemia With or Without Gout

Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study)

Sponsor: Fuji Yakuhin Co., Ltd.

Conditions Hyperuricemia With or Without Gout

Interventions FYU-981

Updated 8 times since 2017 Last updated: Dec 4, 2018 Started: Dec 31, 2016 Primary completion: Aug 23, 2018 Completion: Oct 24, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hyperuricemia With or Without Gout, this trial is completed. The trial is conducted by Fuji Yakuhin Co., Ltd. and has accumulated 8 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2019 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jun 2018 — Jan 2019 [monthly]

Active Not Recruiting PHASE3

▶ Show 3 earlier versions

Oct 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
May 2017 — Oct 2017 [monthly]

Recruiting PHASE3
Jan 2017 — May 2017 [monthly]

Recruiting PHASE3

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuji Yakuhin Co., Ltd.
Mochida Pharmaceutical Company, Ltd.

Data source: Fuji Yakuhin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan